Peritoneal Cancer Pipeline: 55+ Pioneering Companies Driving the Future of Oncology | DelveInsight

The fight against peritoneal cancer is entering an exciting new era, powered by relentless innovation and scientific breakthroughs. Over 55 cutting-edge companies-including industry leaders like Zentalis Pharmaceuticals, Zenith Epigenetics, Mersana Therapeutics, Seagen, Sutro Biopharma, and Shattuck Labs-are redefining what's possible in cancer care. From advanced targeted therapies to next-generation treatment strategies, these pioneers are transforming the peritoneal cancer landscape and igniting new hope for patients worldwide.

DelveInsight's "Peritoneal Cancer Pipeline Insight, 2025" comprehensively analyzes the current clinical landscape and growth prospects in the Peritoneal Cancer market. The report covers disease insights, treatment guidelines, and a detailed pipeline assessment from preclinical to marketed stages. It includes drug mechanisms, clinical studies, regulatory progress, and key developments such as collaborations, mergers, funding, and designations.

For emerging peritoneal cancer drugs, the Peritoneal Cancer pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.

Key Takeaways from the Peritoneal Cancer Pipeline Report
• DelveInsight's peritoneal cancer pipeline analysis depicts a robust space with 55+ active players working to develop 60+ pipeline drugs for Peritoneal Cancer treatment.
• The leading peritoneal cancer companies include Zentalis Pharmaceuticals, Zenith Epigenetics, Mersana Therapeutics, Seagen, Sutro Biopharma, Shattuck Labs, Clover Biopharmaceuticals, Rhizen Pharmaceutical, Oncoinvent, ImmunoGen, Arsenal Biosciences, EMD Serono Research & Development Institute, Medicenna Therapeutics, Array BioPharma, and others are evaluating their lead assets to improve the Peritoneal Cancer treatment landscape.
• Key peritoneal cancer pipeline therapies in various stages of development include Azenosertib, ZEN003694, XMT-1660, Tisotumab vedotin, STRO-002, SL-172154, SCB-313, RP12146, Radspherin, IMGN151, AB-1015, M6620, MDNA11, MEK162, and others.
• In August 2024, the FDA granted orphan drug designation to NXP800, a novel GCN2 kinase activator, for the treatment of ARID1a-deficient ovarian, fallopian tube, and primary peritoneal cancers. The candidate is currently being evaluated in a Phase 1b clinical trial (NCT05226507).
• In June 2024, Oncoinvent received FDA fast-track designation for Radspherin, its therapy targeting peritoneal metastases from ovarian cancer. This designation aims to accelerate the development and review of promising therapies addressing serious conditions with unmet medical needs.

Request a sample and discover the recent breakthroughs happening in the peritoneal cancer pipeline landscape @ https://www.delveinsight.com/report-store/peritoneal-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Peritoneal Cancer Overview
Peritoneal surface malignancy, or peritoneal cancer (PC), involves the spread of malignant cells across the abdominal cavity's lining and organs. It is classified as either primary, such as extraovarian primary peritoneal carcinoma (EOPPC), originating from the mesothelium, or secondary, resulting from metastasis of cancers like ovarian, colorectal, or gastric.

Symptoms are often vague and include abdominal bloating, pain, indigestion, changes in bowel habits, frequent urination, appetite loss, weight changes, and, in advanced cases, ascites, nausea, and fatigue.

Diagnosis typically involves a medical history review, physical exam, and imaging (CT, MRI, PET-CT) to assess disease extent. Laparoscopy is a key procedure for confirming diagnosis and determining eligibility for cytoreductive surgery (CRS) and HIPEC, a heated intraperitoneal chemotherapy used to treat peritoneal cancer.

Treatment includes:
• Surgery (exploratory or cytoreductive) to remove tumors from the peritoneum.
• Chemotherapy, often using drugs similar to those for ovarian cancer, is administered intravenously on a regular outpatient schedule.
• Targeted therapy, including bevacizumab (Avastin) to block tumor blood vessels, and PARP inhibitors to disrupt tumor cell repair mechanisms.

Specialized centers like UT Southwestern offer advanced procedures like CRS and HIPEC, which have improved outcomes and survival in selected patients. Early detection remains difficult due to nonspecific symptoms, making timely medical evaluation essential.

Find out more about peritoneal cancer medication @ https://www.delveinsight.com/report-store/peritoneal-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Peritoneal Cancer Treatment Analysis: Drug Profile
Masitinib: AB Science
Masitinib is an oral tyrosine kinase inhibitor that selectively targets key kinases involved in immune regulation, particularly those affecting mast cells and macrophages, while avoiding kinases linked to toxicity at therapeutic doses. With its distinctive mechanism, Masitinib is being explored across various indications, including oncology, inflammatory disorders, and central nervous system diseases. In peritoneal cancer, it functions by inhibiting kinases such as KIT and PDGFR, which are essential to tumor development and progression. Masitinib is currently in Phase III clinical trials for the treatment of peritoneal cancer.

Azenosertib: Zentalis Pharmaceuticals
Azenosertib is a novel, potentially first- and best-in-class small molecule inhibitor of Wee1, a DNA damage response kinase. By blocking Wee1, Azenosertib forces cancer cells into mitosis without allowing time for DNA repair, leading to cell death. With no FDA-approved Wee1 inhibitors currently available, Azenosertib stands out due to its enhanced selectivity and favorable pharmacokinetic profile. It is currently being evaluated in Phase II clinical trials for the treatment of peritoneal cancer.

Key Peritoneal Cancer Therapies and Companies
• Masitinib: AB Science
• Azenosertib: Zentalis Pharmaceuticals
• IMGN151: ImmunoGen

Learn more about the novel and emerging peritoneal cancer pipeline therapies @ https://www.delveinsight.com/report-store/peritoneal-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Peritoneal Cancer Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.

By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

By Route of Administration
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

By Molecule Type
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Scope of the Peritoneal Cancer Pipeline Report
• Coverage: Global
• Key Peritoneal Cancer Companies: Zentalis Pharmaceuticals, Zenith Epigenetics, Mersana Therapeutics, Seagen, Sutro Biopharma, Shattuck Labs, Clover Biopharmaceuticals, Rhizen Pharmaceutical, Oncoinvent, ImmunoGen, Arsenal Biosciences, EMD Serono Research & Development Institute, Medicenna Therapeutics, Array BioPharma, and others.
• Key Peritoneal Cancer Pipeline Therapies: Azenosertib, ZEN003694, XMT-1660, Tisotumab vedotin, STRO-002, SL-172154, SCB-313, RP12146, Radspherin, IMGN151, AB-1015, M6620, MDNA11, MEK162, and others.

Dive deep into rich insights for drugs used for peritoneal cancer treatment; visit @ https://www.delveinsight.com/report-store/peritoneal-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Table of Contents
1. Introduction
2. Executive Summary
3. Peritoneal Cancer Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Peritoneal Cancer Pipeline Therapeutics
6. Peritoneal Cancer Pipeline: Late-Stage Products (Phase III)
7. Peritoneal Cancer Pipeline: Late-Stage Products (Phase III)
8. Peritoneal Cancer Pipeline: Mid-Stage Products (Phase II)
9. Peritoneal Cancer Pipeline: Early Stage Products (Phase I)
10. Therapeutic Assessment
11. Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Key Companies
14. Key Products
15. Unmet Needs
16. Market Drivers and Barriers
17. Future Perspectives and Conclusion
18. Analyst Views
19. Appendix

Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform, PharmDelve.

This release was published on openPR.